Zydus Lifesciences Ltd saw a 2% surge in its share price, hitting a fresh 52-week high on Thursday following positive developments at its Ahmedabad facility. The United States Food and Drug Administration (FDA) issued a favourable "post-application action letter" after inspecting the facility, indicating readiness for commercial production of Enzalutamide, a medication used to treat prostate cancer.
The inspection, which covered for-cause current Good Manufacturing Practices (cGMP) surveillance and pre-approval inspection for Enzalutamide, took place from December 14-22, 2023. Zydus Lifesciences informed the stock exchanges about this development in a filing.
The receipt of a positive post-application action letter from the US FDA signifies that the inspected facility is deemed ready for the commercial manufacture and supply of Enzalutamide API.
This positive news propelled the shares of Zydus Lifesciences, witnessing a rise of up to 2.08% to reach a 52-week high of ₹982.1 apiece on the BSE, consequently elevating the company's market valuation to over ₹99,000 Crore.
Earlier in January, Zydus Lifesciences' wholly-owned subsidiary secured an exclusive licensing and supply arrangement with Synthon for Palbociclib Tablets, targeting the US market. This collaboration with Synthon, the initial and sole Abbreviated New Drug Application (ANDA) filer for Palbociclib Tablets in various strengths, could potentially qualify for 180 days of exclusivity for generic drug distribution.
Moreover, in December 2023, Zydus Lifesciences announced its approval from the US health regulator to market a generic product addressing a rare blood condition.
As of 11:39 AM, shares of Zydus Lifesciences were trading 1.35% higher at ₹974.85 apiece on the NSE.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.